Chinese Journal of Catalysis ›› 2023, Vol. 47: 1-31.DOI: 10.1016/S1872-2067(22)64207-4

• Review •     Next Articles

Heteronuclear dual-metal atom catalysts for nanocatalytic tumor therapy

Jingyi Han, Jingqi Guan*()   

  1. Institute of Physical Chemistry, College of Chemistry, Jilin University, Changchun 130021, Jilin, China
  • Received:2022-10-30 Accepted:2022-12-01 Online:2023-04-18 Published:2023-03-20
  • Contact: *E-mail: guanjq@jlu.edu.cn (J. Guan).
  • About author:Jingqi Guan (Jilin University) was invited as a young member of the 6th Editorial Board of Chin. J. Catal. and the 5th Editorial Board of Acta Phys.-chim. Sin. Prof. Jingqi Guan received his B.A. degree in 2002 and Ph.D. degree in 2007 from Jilin University. He carried out postdoctoral research in the University of California at Berkeley from 2012 to 2013 and in Dalian Institute of Chemical Physics, Chinese Academy of Sciences from 2014 to 2018. His research interests are in engineering single-atom catalysts and 2D materials for electrocatalysis, renewable energy, and biosensors. He has published more than 180 peer-reviewed papers.
  • Supported by:
    National Natural Science Foundation of China(22075099);Natural Science Foundation of Jilin Province(20220101051Jc);Education Department of Jilin Province(JJKH20220967KJ)

Abstract:

Due to excellent catalytic activity and high atomic utilization rate, single atom catalysts (SACs) have become a rising star in the field of nanocatalytic medicine. Heteronuclear dual-atom catalysts (HDACs) retain the advantages of monoatomic catalysts, have more optionally regulated coordination environment, possess favorable synergistic effects between different active sites, and can break through the restriction of adsorption ratio of SACs, making them the most ideal candidates for catalytic tumor therapy. In this review, we first introduce the advanced characterization methods of HDACs. Then, HDACs in different application fields are classified and elaborated according to various preparation strategies. According to the pharmacodynamic mechanisms, the application of HDACs in the field of nanocatalytic tumor therapy is emphatically introduced. Finally, a concise but focused summary and perspective is provided to outline the current challenges and prospects for future development of HDACs for oncology therapy.

Key words: Heteronuclear, Dual-atom catalyst, Tumor therapy, Reactive oxygen, Fenton-like reaction